Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19...
The cancer biotech is laying off one-fifth of its staff and scrapping three drugs, while Novartis has secured sufficient shareholder support for its $3B acquisition.
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information “ Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under...
Galapagos bolsters decentralized CAR-T manufacturing
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid...
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with...
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company's Annual and Extraordinary Shareholders™ Meetings...
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT) ...
Publication of annual report for financial year 2023Annual Shareholders™ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary...
Galapagos appoints Dickinson as Non-Executive independent Director to its Board